SUPN vs. KNSA, INVA, ARQT, OCUL, ORIC, PRGO, CORT, PCRX, NKTR, and OMER
Should you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Kiniksa Pharmaceuticals (KNSA), Innoviva (INVA), Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), ORIC Pharmaceuticals (ORIC), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), and Omeros (OMER). These companies are all part of the "pharmaceutical preparations" industry.
Supernus Pharmaceuticals (NASDAQ:SUPN) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking.
Kiniksa Pharmaceuticals has a net margin of 2.78% compared to Supernus Pharmaceuticals' net margin of -2.60%. Supernus Pharmaceuticals' return on equity of -1.68% beat Kiniksa Pharmaceuticals' return on equity.
In the previous week, Supernus Pharmaceuticals had 3 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 4 mentions for Supernus Pharmaceuticals and 1 mentions for Kiniksa Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.60 beat Kiniksa Pharmaceuticals' score of 0.00 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.
Supernus Pharmaceuticals presently has a consensus target price of $41.00, indicating a potential upside of 56.13%. Kiniksa Pharmaceuticals has a consensus target price of $31.00, indicating a potential upside of 62.64%. Given Kiniksa Pharmaceuticals' higher probable upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Supernus Pharmaceuticals.
Supernus Pharmaceuticals received 305 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 64.34% of users gave Kiniksa Pharmaceuticals an outperform vote.
Supernus Pharmaceuticals has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500.
54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Kiniksa Pharmaceuticals has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Kiniksa Pharmaceuticals beats Supernus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Supernus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Supernus Pharmaceuticals Competitors List
Related Companies and Tools
